Date: 2014-11-06
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Francisco, California from December 6-9, 2014.
Company: Geron (USA - CA)
Product: imetelstat
Action mechanism:
Disease: myelofibrosis, acute myeloid leukemia
Therapeutic area: Rare diseases
Country:
Trial details:
Latest
news: * On November 6, 2014, Geron announced that five abstracts describing clinical and non-clinical data on imetelstat have been accepted for presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Francisco, California from December 6-9, 2014. Two abstracts containing clinical data on imetelstat were selected for oral presentation. One abstract contains an analysis of safety and efficacy data from the clinical trial in myelofibrosis (MF) patients. The abstract updates the preliminary data from this trial that was presented at ASH in December 2013. The second abstract contains an analysis of the effect of imetelstat treatment on CALR mutations detected in essential thrombocythemia patients. The abstract supplements a prior analysis of JAK2V617F mutations presented at the European Hematology Association Congress in June 2013. Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study (Abstract #634) identifies imetelstat as an active drug in patients with MF, but also reveals its potential to cause significant myelosuppression. Monitoring of CALR Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses (Abstract #408) Three abstracts containing non-clinical data on imetelstat were also selected for presentation as posters. In these studies, the investigators evaluated the potential mechanisms of action of imetelstat in various non-clinical models of myeloid malignancies, such as MF and acute myeloid leukemia, to support broader clinical development of the drug. Effects of Imetelstat on CD34+ Cells of Patients with Myelofibrosis (Abstract #1879) suggests that imetelstat is capable of selectively promoting the apoptosis and inhibiting the proliferation of phenotypically and functionally defined MF but not normal CD34+ cells. Inhibition of Telomerase with Imetelstat is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML) (Abstract #2322) shows the efficacy of pharmacologic inhibition of telomerase using imetelstat in human AML and proposes a novel paradigm of AML therapy that is to delay or prevent relapse by targeting AML stem cells in vivo.Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN) (Abstract #4582)
